secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tectonic Therapeutic, Inc. (TECX)
CIK:        0001681087
Form:       8-K
Filed at:   2026-06-10T21:08:54+00:00
Accession:  0001193125-26-266040
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tectonic completes enrollment in Phase 2 TX45 trial for PH-HFpEF; topline data expected early Q1 2027
--------------------------------------------------------------------------------

- APEX trial enrolled 191 patients across 14 countries; 72% (137 pts) in enriched CpcPH subset (PVR > 3 WU).
- Mean baseline PVR: 4.2 WU overall; 5.2 WU in CpcPH subset.
- Topline results from Phase 2 APEX study expected in early Q1 2027.
- Two dose regimens of TX45 (300 mg monthly or every other week) vs placebo; primary endpoint is change in PVR.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681087/000119312526266040/0001193125-26-266040-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681087/000119312526266040/d124600d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-266040

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer